Subproject 1: Optimize prevention after acute coronary syndromes (ACS) by improving caregiver and patient education (http://elips.hug-ge.ch/eng/index\_eng2.htm) Subproject 2: Discover novel genomic biomarkers of ACS in leukocyte subsets by means of analyzing gene expression profiles and function Subproject 3: Evaluate novel diagnostic and prognostic biomarkers in soluble form in blood/plasma and urine Subproject 5: Visualize the vulnerable plaque using intravascular ultrasound/optical coherence tomography (IVUS/OCT) and correlate with outcome and biomarkers Subproject 7: Characterize the effects of inflammation on progenitor/stem cell-mediated repair after ACS by means of analyzing gene expression profiles and function
Study Type
OBSERVATIONAL
Enrollment
4,000
University Hospital, Geneva
Geneva, Canton of Geneva, Switzerland
RECRUITINGUniversity Hospital, Bern
Bern, Switzerland
RECRUITINGUniversity Hospital, Lausanne
Lausanne, Switzerland
RECRUITINGUniversity Hospital, Zurich
Zurich, Switzerland
RECRUITINGMajor adverse cardiovascular events (MACE) in overall population, defined as composite of cardiac death, myocardial infarction or ischemia-driven revascularization
Time frame: 30 days and 12 months follow-up
SP2/SP3/SP5: temporal change in biomarkers (12 months).
Time frame: SP2/SP3/SP5: 13 months
Correlation with plaque burden and neointimal thickness assessed by IVUS/OCT imaging in ST segment elevation myocardial infarction (STEMI) subgroup (13 months)
Time frame: 13 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.